Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Average urinary cannabinoids, measuring THC, during cannabis use disorder treatment trials appear to differ between participants with and without self-reported cannabis use reduction. Urinary cannabinoids appear to decrease concurrently with self-reported use reduction, with a 50% average decrease being observed among those self-reporting reductions. Overall classification models did not yield a urinary creatinine-normalized cannabinoids cut-off that could be used for individuals to detect meaningful cannabis reduction. Individual-based biochemical verification of cannabis reduction will require further work to establish, though average reductions of at least 50% in urinary cannabinoids may be a useful metric for the majority of those with cannabis use disorder in clinical and research settings.